Live Feeds
● LIVE Updated 1h ago · 16 sources tracked

ROBERT F. KENNEDY JR.: The future of medicine should be built in America

HHS Secretary Robert F. Kennedy Jr. is pursuing a strategy to build the future of medicine within the United States. This effort focuses on reshoring pharmaceutical production and speeding up clinical research. The goal is to reduce reliance on foreign supply chains and counter China's lead in early trials.

RSS Source map (16)

What changed

New FDA estimates suggest the HHS initiative could reduce development timelines by 6 to 12 months.

Live updates

  1. RFK Jr. Launches Initiative to Accelerate US Drug Development

    HHS Secretary Robert F. Kennedy Jr. is pursuing a strategy to build the future of medicine within the United States. This effort focuses on reshoring pharmaceutical production and speeding up clinical research. The goal is to reduce reliance on foreign supply chains and counter China's lead in early trials.

    What's confirmed:

    • Secretary Robert F. Kennedy Jr. is leading an effort to reshore pharmaceutical manufacturing and accelerate clinical research.
    • The HHS initiative aims to counter China's lead in early-stage clinical trials.

    Still unconfirmed:

    • The FDA estimates the interagency initiative could shorten development timelines by 6 to 12 months.
    confidence 90%

  2. HHS Secretary Kennedy Pushes for US-Led Medical Innovation

    Health and Human Services Secretary Robert F. Kennedy Jr. is leading an effort to reshore pharmaceutical manufacturing and accelerate clinical research. The initiative aims to counter China's growing lead in early-stage clinical trials. The White House has expressed support for reducing reliance on foreign drug supply chains.

    What's confirmed:

    • HHS Secretary Robert F. Kennedy Jr. stated that the future of medicine should be built in America.
    • China currently conducts more early-stage clinical trials than the United States.
    • Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity in 2025.
    • The FDA is leading a pilot initiative called Operation TrialBlazer to speed up early drug research.
    • The FDA estimates that the new multi-agency effort could reduce development timelines by 6 to 12 months.

    Still unconfirmed:

    • China is quietly taking control of US medicine.
    • The US leads in biotech quality and commercial reach.
    • Some researchers are looking abroad due to Trump cutting science budgets.
    confidence 95%